FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2254870307> ?p ?o ?g. }

• W2254870307 endingPage "e19011" @default.
• W2254870307 startingPage "e19011" @default.
• W2254870307 abstract "e19011 Background: Fotemustine is a third-generation nitrosourea authorized in Europe for the treatment of metastatic melanoma. Fotemustine crosses the brain-blood barrier with a relevant activity on brain metastases (BM) and it is authorized in some European countries for primary brain tumors. Methods: We assessed the pattern of use, efficacy (tumor response, median progression-free survival [PFS], and median overall survival [OS]) and toxicity of fotemustine in Spain through a retrospective study on medical record data of 170 patients (pts) (56% male, 44% female). Median age: 61 years (range 20–87). ECOG PS: 0 in 28% of pts, 1 in 55%, ≥ 2 in 17%. High LDH values: 42 pts. Results: The most used scheme was induction at a 100 mg/m2 i.v. dose (days 1, 8, 15), 4-5 weeks of therapeutic rest and maintenance (100 mg/m2 i.v. every 3 weeks). 41% of pts were treated in first line, 38% in second, and 21% in third or higher. The median number of cycles was 3 (range 1-10). 160 pts were evaluable for efficacy. Tumor response: 3% complete response (CR), 14% partial response (PR), 31% stable disease (SD), 52% progression disease (PD). The clinical benefit in first line was 61% (CR=5%, PR=14%, SD=42%) and 39% (CR=3%, PR=14%, SD=22%) in second line. PFS was 84 days (95% CI 71-109), 100 days (95% CI 72-127) in first line and 77 days (95% CI 63-110) in second line. OS was 200 days (6.5 months) (95% CI 172–284). In 17 pts (10.3%) with BM the tumor response was CR=6% (1 pt), PR=18% (3 pts), SD=35% (6 pts), PD=41% (7 pts). 165 pts were evaluable for toxicity. The most common grade 3/4 toxicities were hematological and included neutropenia (40 pts, 24.2%), thrombocytopenia (39 pts, 23.6%), and anemia (14 pts, 8.5%). Conclusions: Fotemustine is an active and well-tolerated agent in metastatic melanoma, including brain metastases. Tumor response n % CR 5 3 PR 23 14 SD 49 31 Clinical benefit (CR+PR+SD) 77 48 PD 83 52 Total 160 100 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Italfarmaco, S.A." @default.
• W2254870307 created "2016-06-24" @default.
• W2254870307 creator A5003161652 @default.
• W2254870307 creator A5005987696 @default.
• W2254870307 creator A5012702634 @default.
• W2254870307 creator A5019869973 @default.
• W2254870307 creator A5025443187 @default.
• W2254870307 creator A5030110619 @default.
• W2254870307 creator A5061695890 @default.
• W2254870307 creator A5068271097 @default.
• W2254870307 creator A5084511205 @default.
• W2254870307 creator A5085476251 @default.
• W2254870307 date "2010-05-20" @default.
• W2254870307 modified "2023-09-23" @default.
• W2254870307 title "Retrospective study of the efficacy and safety of fotemustine in 170 patients with metastatic melanoma." @default.
• W2254870307 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e19011" @default.
• W2254870307 hasPublicationYear "2010" @default.
• W2254870307 type Work @default.
• W2254870307 sameAs 2254870307 @default.
• W2254870307 citedByCount "0" @default.
• W2254870307 crossrefType "journal-article" @default.
• W2254870307 hasAuthorship W2254870307A5003161652 @default.
• W2254870307 hasAuthorship W2254870307A5005987696 @default.
• W2254870307 hasAuthorship W2254870307A5012702634 @default.
• W2254870307 hasAuthorship W2254870307A5019869973 @default.
• W2254870307 hasAuthorship W2254870307A5025443187 @default.
• W2254870307 hasAuthorship W2254870307A5030110619 @default.
• W2254870307 hasAuthorship W2254870307A5061695890 @default.
• W2254870307 hasAuthorship W2254870307A5068271097 @default.
• W2254870307 hasAuthorship W2254870307A5084511205 @default.
• W2254870307 hasAuthorship W2254870307A5085476251 @default.
• W2254870307 hasConcept C121608353 @default.
• W2254870307 hasConcept C126322002 @default.
• W2254870307 hasConcept C141071460 @default.
• W2254870307 hasConcept C143998085 @default.
• W2254870307 hasConcept C167135981 @default.
• W2254870307 hasConcept C2776694085 @default.
• W2254870307 hasConcept C2777658100 @default.
• W2254870307 hasConcept C2778822529 @default.
• W2254870307 hasConcept C2780739268 @default.
• W2254870307 hasConcept C29730261 @default.
• W2254870307 hasConcept C2994587330 @default.
• W2254870307 hasConcept C502942594 @default.
• W2254870307 hasConcept C71924100 @default.
• W2254870307 hasConcept C90924648 @default.
• W2254870307 hasConceptScore W2254870307C121608353 @default.
• W2254870307 hasConceptScore W2254870307C126322002 @default.
• W2254870307 hasConceptScore W2254870307C141071460 @default.
• W2254870307 hasConceptScore W2254870307C143998085 @default.
• W2254870307 hasConceptScore W2254870307C167135981 @default.
• W2254870307 hasConceptScore W2254870307C2776694085 @default.
• W2254870307 hasConceptScore W2254870307C2777658100 @default.
• W2254870307 hasConceptScore W2254870307C2778822529 @default.
• W2254870307 hasConceptScore W2254870307C2780739268 @default.
• W2254870307 hasConceptScore W2254870307C29730261 @default.
• W2254870307 hasConceptScore W2254870307C2994587330 @default.
• W2254870307 hasConceptScore W2254870307C502942594 @default.
• W2254870307 hasConceptScore W2254870307C71924100 @default.
• W2254870307 hasConceptScore W2254870307C90924648 @default.
• W2254870307 hasIssue "15_suppl" @default.
• W2254870307 hasLocation W22548703071 @default.
• W2254870307 hasOpenAccess W2254870307 @default.
• W2254870307 hasPrimaryLocation W22548703071 @default.
• W2254870307 hasRelatedWork W138302248 @default.
• W2254870307 hasRelatedWork W2027230955 @default.
• W2254870307 hasRelatedWork W2028195960 @default.
• W2254870307 hasRelatedWork W2054476072 @default.
• W2254870307 hasRelatedWork W2190337945 @default.
• W2254870307 hasRelatedWork W2254812154 @default.
• W2254870307 hasRelatedWork W2289813745 @default.
• W2254870307 hasRelatedWork W2419299658 @default.
• W2254870307 hasRelatedWork W2891648747 @default.
• W2254870307 hasRelatedWork W3193367738 @default.
• W2254870307 hasVolume "28" @default.
• W2254870307 isParatext "false" @default.
• W2254870307 isRetracted "false" @default.
• W2254870307 magId "2254870307" @default.
• W2254870307 workType "article" @default.